Vmbook Online ordering
Biotechnology
Alexo Therapeutics, Inc. (ALXN) is a public biotech company listed on the US stock exchange. The company focuses on developing and commercializing life-changing therapies for people with severe diseases. Here are key aspects of Alexo Therapeutics, Inc.:
* Year of foundation: 2013
* Scientific founder: Martin Mackay, Ph.D.
* CEO: Scott Tarriff
* Headquarters: Philadelphia, Pennsylvania
* Number of employees: 300-500 employees
* MarketCap: 6.36 B USD
* Stocks: ALXN
* Sector: Biotech
* Sector performance: 13.32%
* Industry: Pharmace We focus on three therapeutic areas: oncology, rare disease, and autoimmune disorders. Their mission is to harness the body's immune system to fight disease and improve patient outcomes.
Alexo Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing and commercializing life-changing therapies for people with severe diseases. The company aims to transform patients' lives by harnessing the powerful science of immunotherapy to fight disease and improve patient outcomes. Their pipeline includes several clinical-stage programs, including Ultomiris (ravulizumab-cwvz) in paroxysmal nocturnal hemoglobinuria (PNH) and gMG, ALX148 in r/r MM, and ALX148 in a Phase 1b/2 study for PNH, among others.
The company's flagship product, Ultomiris, is a long-acting C5 compliment inhibitor administered intravenously every eight weeks for at one of four weight-based dose regimens for adult PNH patients. It is also administered weekly or every two weeks at one of two doses for adult and pediatric patients with generalized myasthenia gravis (GMG).
Alexo Therapeutics, Inc. has established partnerships with leading organizations, including the National Cancer Institute, Biomedical Advanced Research and Development Authority (BARDA),National Institutes of Health, and medical oncologists. These partnerships have enabled the company to develop and advance its pipeline of immunotherapies to address significant patient needs.
The company's long-term growth trajectory is expected to be promising, with several catalysts to drive growth. The company has a solid pipeline with four clinical-stage assets, including the commercially approved Ultomiris program. Additionally, the company's efforts to develop a B-cell targets portfolio are underway. The core technology of the company is based on the research from the lab of Martin Mackay, Ph.D.
Alexo Therapeutics, Inc. has a strong presence in the US market with its stock symbol ALXN and is listed on the NASDAQ stock exchange. The company has a solid track record of advancing innovative therapies in oncology and autoimmune diseases, making it an attractive investment opportunity for investors seeking growth in the biotechnology sector.
It is essential to thoroughly research, analyze financial statements, and consult financial advisors before investing in stocks.